Payment overview · 2025
General Payments
$283.07
16 reported records · 6 companies
Healthcare provider profile · identity verified
Michael J Gipson, MD
Allopathic & Osteopathic Physicians|Family Medicine · TUPELO, MS · NPI 1740201078
Verified facts
What the public records show
CMS Open Payments records show Michael J Gipson, MD received $283.07 in general payments during 2025 across 16 reported records.
Lilly USA, LLC accounted for 45.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Nurtec Odt.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $128.70 | 45.5% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $41.71 | 14.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $35.98 | 12.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.94 | 12.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.70 | 9.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.04 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $283.07 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $112.89 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $72.28 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $41.71 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.98 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $33.94 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.70 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 96 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
54 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
96 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 455 | 184 |
| Gabapentin | Gabapentin | 414 | 152 |
| Atorvastatin Calcium | Atorvastatin Calcium | 406 | 176 |
| Amlodipine Besylate | Amlodipine Besylate | 395 | 176 |
| Losartan Potassium | Losartan Potassium | 378 | 151 |
| Omeprazole | Omeprazole | 330 | 133 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 118 |
| Lisinopril | Lisinopril | 277 | 109 |
| Montelukast Sodium | Montelukast Sodium | 272 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 76 |
| Metformin Hcl | Metformin Hcl | 205 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 203 | 81 |
| Meloxicam | Meloxicam | 201 | 71 |
| Zolpidem Tartrate | Zolpidem Tartrate | 178 | 68 |
| Carvedilol | Carvedilol | 177 | 72 |
| Furosemide | Furosemide | 171 | 77 |
| Famotidine | Famotidine | 170 | 62 |
| Metformin Hcl Er | Metformin Hcl | 167 | 67 |
| Alprazolam | Alprazolam | 149 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 149 | 62 |
| Tizanidine Hcl | Tizanidine Hcl | 146 | 50 |
| Trazodone Hcl | Trazodone Hcl | 145 | 61 |
| Tramadol Hcl | Tramadol Hcl | 136 | 45 |
| Simvastatin | Simvastatin | 132 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 129 | 55 |
| Allopurinol | Allopurinol | 128 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 114 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 37 |
| Glimepiride | Glimepiride | 105 | 44 |
| Clonazepam | Clonazepam | 99 | 29 |
| Potassium Chloride | Potassium Chloride | 98 | 48 |
| Spironolactone | Spironolactone | 97 | 37 |
| Eliquis | Apixaban | 96 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 38 |
| Ezetimibe | Ezetimibe | 91 | 42 |
| Sertraline Hcl | Sertraline Hcl | 90 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 88 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 74 | 60 |
| Pregabalin | Pregabalin | 74 | 25 |
| Buspirone Hcl | Buspirone Hcl | 70 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 28 |
| Ozempic | Semaglutide | 69 | 22 |
| Meclizine Hcl | Meclizine Hcl | 68 | 27 |
| Valacyclovir | Valacyclovir Hcl | 68 | 28 |
| Lovastatin | Lovastatin | 67 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 28 |
| Ibuprofen | Ibuprofen | 64 | 18 |
| Donepezil Hcl | Donepezil Hcl | 62 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 31 |
| Dicyclomine Hcl | Dicyclomine Hcl | 54 | 20 |
| Jardiance | Empagliflozin | 54 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 53 | 23 |
| Januvia | Sitagliptin Phosphate | 52 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 50 | 17 |
| Diazepam | Diazepam | 49 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 15 |
| Memantine Hcl | Memantine Hcl | 42 | 18 |
| Bupropion Xl | Bupropion Hcl | 41 | 17 |
| Mirtazapine | Mirtazapine | 41 | 19 |
| Alendronate Sodium | Alendronate Sodium | 39 | 13 |
| Prednisone | Prednisone | 39 | 23 |
| Methocarbamol | Methocarbamol | 38 | 15 |
| Estradiol | Estradiol | 37 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 34 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | 20 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | 12 |
| Farxiga | Dapagliflozin Propanediol | 31 | 14 |
| Fluconazole | Fluconazole | 31 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 26 |
| Linzess | Linaclotide | 28 | 14 |
| Torsemide | Torsemide | 28 | 12 |
| Finasteride | Finasteride | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 26 | suppressed |
| Lansoprazole | Lansoprazole | 26 | 12 |
| Propranolol Hcl | Propranolol Hcl | 26 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 16 |
| Aripiprazole | Aripiprazole | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Nystatin | Nystatin | 24 | 16 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 20 | 11 |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | 13 |
| Lactulose | Lactulose | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 13 |
| Trulicity | Dulaglutide | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 12 |
| Atenolol | Atenolol | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Baclofen | Baclofen | 15 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Naproxen | Naproxen | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $283.07 · 16 records | Lilly USA, LLC | AIRSUPRA, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, KISUNLA, MOUNJARO, NURTEC ODT, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error